Skip to NavigationSkip to content

Pfizer takes legal action against Indian drugmakers over generic cancer drug

Published on 17/11/20 at 12:49pm
Photo by Pravbv

Pfizer has filed a petition in a US court against Indian companies Dr Reddy’s Laboratories and Aurobindo Pharma that alleges the pair were planning to release generic versions of Ibrance before the expiration of Pfizer’s patent. 

Pfizer filed the possible patent infringement petition against both companies in the District Court for the District of Delaware. 

The company said: “In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the US Food and Drug Administration (FDA) seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of two compositions of matter patents and a method of patent covering palbociclib, each of which expires in 2023.”

Pfizer said in its petition that the Indian drugmakers had submitted abbreviated new drug applications to the FDA to engage in the commercial manufacturer, sale and importation of generic versions of Ibrance. Pfizer is seeking an injunction to stop the companies from creating their generic version. 

Ibrance (palbociclib) is used to treat breast cancer and works to stop the growth of cancer cells. It has generated nearly $5 billion in revenue, with $3.25 billion coming in 2019, according to a Pfizer report. 

Conor Kavanagh

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches